SAVE $230: The Vitamix A3300 is on sale for $499.95 in the Amazon Prime Big

In the western German village of Lohne, where the only grocery store closed its doors earlier this year, residents now do their food shopping on board a red-and-green supermarket bus that rolls...

Volvo's got a new electric SUV coming. The company hasn't given us much, though, beyond

Fishermen in the U.S.’s only commercial-scale fishing industry for valuable baby eels once again had a productive season searching for the tiny fish

The Duchess of York will make her debut on ITV’s Loose Women to launch a breast cancer awareness campaign following her treatment for the illness earlier this year. Sarah Ferguson underwent an eight-hour single mastectomy operation after discovering she had an early form of breast cancer during a routine mammogram. The special episode, billed as Ferguson’s first TV appearance since revealing her diagnosis, will launch its “Don’t Skip Your Screening” campaign to highlight the importance of being checked for cancer. The duchess will join presenters Christine Lampard, Coleen Nolan and Brenda Edwards on the show’s panel to discuss the campaign and her own experiences since being diagnosed with breast cancer. Ahead of the show on Thursday (2 November), Ferguson revealed she nearly skipped the screening appointment “that saved my life” adding that her cancer journey “underlines the importance of getting screened” regularly. “I couldn’t face a journey into London on a hot day this summer and it was only my sister Jane’s insistence that I went, that persuaded me,” the mother-of-two said. “My cancer was completely symptom-free – I never found a lump and did not feel ill.” Doctors noticed a “shadow” in one of her breasts during the screening in May, which was later diagnosed as cancer. Ferguson added that she is “proud” to support the campaign, which is being backed by NHS England, to encourage other women to attend the appointments when they are invited. In July, Ferguson confirmed she underwent an eight-hour-long single mastectomy, adding that the diagnosis was “scary” for her daughters, Princesses Beatrice and Eugenie, during an episode of her podcast Tea Talks. She said: “I think it’s scary for any family member out there, you really start looking at your own demise. It’s a wake up call, and you think, right okay, how am I going to deal with this?” Ferguson also advised her listeners to “do the screening, catch it quick”, while thanking the medical professionals at King Edward VII’s Hospital in London for their care and treatment. Earlier this year, Ferguson also explained how the mastectomy helped her overcome the “self-hatred that stemmed from years of being compared to Diana. During a separate episode of her podcast, Ferguson suggested she had to have a “body part cut off” before she could “wake up”. She told her co-host, Sarah Thompson: “Not because of seeing death, but waking up to stop worrying, stop self-hatred, stop self-doubt, stop all these things. Stop not liking yourself, really, please, honestly. “Does it take that?... Yes, it did in my case,” Ferguson continued. “[I] didn’t like myself and that was because I think I was always compared to Diana and I think at the end I sort of believed my own press which is not too good.” Charity Breast Cancer Now said it is “extremely grateful” that the show is “shining a bright spotlight on breast screening” and “highlighting the important issue of tackling the shortfall in women having breast screening caused by the Covid-19 pandemic”. In a statement, it added: “Breast screening is a vital tool in helping to detect breast cancer at the earliest possible stage, when treatment is more likely to be successful. “We encourage all women to attend breast screening appointments when invited and to regularly check their breasts, reporting any unusual changes to their GP as soon as possible.” The duchess will join the panel on Loose Women on 2 November from 12:30pm on ITV1 and ITVX. Read More Sarah Ferguson shares heartfelt tribute to Matthew Perry following his death Doctor highlights most commonly misdiagnosed health conditions in women Mom explains how to ‘raise your baby like it’s your third’ Doctor highlights most commonly misdiagnosed health conditions in women Mom explains how to ‘raise your baby like it’s your third’ ‘It was terrifying’: All the things Jada Smith Pinkett has said about her alopecia

Electric cars are widely hailed as the future of transport, but even though they eliminate the issue of fuel emissions from tailpipes, the problem of particle pollution as a result...

ROSEMONT, Ill.--(BUSINESS WIRE)--Jul 12, 2023--

A year after the US Supreme Court abolished nationwide access to abortion care, many American women are settling into a new reality: arranging costly trips to terminate their pregnancies in...

DoorDash Inc. reported a record number of delivery orders in the second quarter, showing consumers’ commitment to takeout

A new survey has found that nearly half of adults in the United States are interested in taking prescription drugs for weight loss, such as Ozempic or Wegovy. In a KFF health tracking poll published on 3 August, researchers reported that 45 per cent of adults said they’d be interested in taking a “safe and effective” prescription drug for weight loss. Meanwhile, seven in 10 adults said they’ve heard at least “a little” about a new class of drugs being used for weight loss, with about one in five saying they have heard “a lot” about these drugs. Ozempic is a type 2 diabetes medication known for its weight loss side effects. Similar semaglutide injections, such as Wegovy and Mounjaro, have been specifically approved for the treatment of obesity and weight loss. This class of drugs called GLP-1 agonists works by mimicking a hormone called glucagon-like peptide 1 (GLP-1), regulating blood sugar levels and slowing down the rate at which food leaves the stomach to create the feeling of fullness. Of the US adults surveyed, older groups were some of the most aware of prescription weight loss drugs, with 76 per cent being those who have been told by a doctor in the past five years that they are overweight or obese. Nearly 60 per cent of those surveyed said they were currently trying to lose weight as well. While there was an overall interest in taking a prescription weight loss drug, that interest significantly decreased when people were asked whether they would take the medication as a routine injection. Only 16 per cent of adults said they would still take Ozempic or Wegovy, even if it wasn’t covered by their health insurance and was not specifically approved by the US Food and Drug Administration for weight loss. In fact, most people believed that insurance companies should cover the cost of weight loss drugs for adults who are overweight or obese, with an overwhelming 80 per cent of adults. Additionally, a large majority of adults believed the substantial profits that pharmaceutical companies have made from increased demand for weight loss drugs is a major factor contributing to the cost of injections like Ozempic and Wegovy. According to Novo Nordisk, the pharmaceutical company behind these prescription drugs for diabetes and weight loss, the list price for Ozempic can cost $935.77 per month without health insurance. Although the majority of adults said they trust pharmaceutical companies like Novo Nordisk to provide “reliable information” about safety and side effects of GLP-1 agonists, only 22 per cent said they trust these companies to price their products fairly. The FDA has listed the most common side effects of taking Wegovy as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, and digestive disorders. More serious complications can occur from use of Wegovy or Mounjaro, such as the “potential risk of thyroid C-cell tumours,” pancreatitis, gallbladder problems, acute kidney injury, increased heart rate, and suicidal behaviour or thinking. Taking Ozempic can also lead to possible thyroid tumours, including cancer, pancreatitis, changes in vision, and kidney and gallbladder problems. Recently, several patients reported suffering from severe gastroparesis, also known as stomach paralysis, after taking the prescription weight loss medications. In a report from CNN, two people claimed that their “stomachs are paralysed” after taking Ozempic. “I wish I never touched it. I wish I’d never heard of it in my life,” Joanie Knight, a 37-year-old from Louisiana, told CNN. “This medicine made my life hell. So much hell. It has cost me money. It cost me a lot of stress; it cost me days and nights and trips with my family. It’s cost me a lot, and it’s not worth it. The price is too high.” One woman was also diagnosed with cyclic vomiting syndrome, which causes her to throw up multiple times a day. “I’ve almost been off Ozempic for a year, but I’m still not back to my normal,” said Emily Wright, a 38-year-old teacher from Toronto. Shortly after the report, the FDA shared in a statement with The Independent that it has become aware of stomach paralysis occurring among patients taking the medications. “The FDA has received reports of gastroparesis with semaglutide and liraglutide, of which some documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said. However, officials clarified that they were unable to determine whether taking Ozempic or Wegovy was the cause of stomach paralysis, or if it was caused by a different issue. “Gastroparesis can be a complication of diabetes that is related to long-standing or poorly controlled disease, further complicating the ability to determine what role the drugs played in the reported events,” the FDA added. In response to reports of stomach paralysis, drug manufacturer Novo Nordisk noted that these medications have been used to treat type 2 diabetes “for more than 15 years”, and for the “treatment of obesity” for eight years. “Semaglutide has been extensively examined in robust clinical development programs, large real world evidence studies and has cumulatively over 9.5 million patient years of exposure,” a spokesperson for Novo Nordisk said in a statement to The Independent. “Gastrointestinal (GI) events are well-known side effects of the GLP-1 class. For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1’s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects.” Read More Obese people on weight-loss jabs ‘should be prepared to stay on them for life’ Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’ Sharon Osbourne says she was ‘nauseous’ for weeks after taking Ozempic to lose weight Sharon Osbourne reveals what Ozempic did to her when she was taking it Ozempic users report stomach paralysis as side effect: ‘I wish I never touched it’ Lorraine Candy: ‘Perimenopausal rage made me unravel’

Audi have revealed former Le Mans winner Neel Jani has joined the team as a simulator driver ahead of their 2026 Formula 1 entry. The German brand, owned by Volkswagen, announced last summer they would enter F1 under new regulations in 2026, building their own power unit in Bavaria. By October, a deal had been struck to take over the Sauber works team, currently branded as Alfa Romeo, in time for 2026. With preparations for their entry well underway, with Andreas Seidl leaving McLaren in December to join as the team’s new CEO, Swiss driver Jani has been announced as a driver to aid development on the power-unit with simulator work. Jani, 39, is a former F1 test and reserve driver for Red Bull and has driven in GP2, Formula E and Le Mans, which he won in 2016 with Porsche. “I am delighted to accompany Audi on their way into Formula 1,” said Jani. “It is both an honour and a great responsibility to be involved in a project of this magnitude at an early stage. “I am sure that with my experience from Formula 1 and LMP [Le Mans Prototype] projects I can forge good links between theory and practice.” Audi are aiming to test their first full power unit by the end of this year. “Just like in production development, simulation plays a major role in our Formula 1 project,” said Oliver Hoffmann, member of the board of management for technical development of Audi AG. “Our simulator is an important tool for the power unit development. It requires a development driver who in addition to a grasp of technology brings versatile experience to the project, especially in terms of energy management in racing conditions.” Audi are a confirmed entry for 2026 while the FIA are currently in the midst of a process of considering other prospective entries from the likes of Andretti-Cadillac, Hitcech GP and Panthera Team Asia. Read More Inspired by Schumacher, meet the Hong Kong billionaire targeting a new Formula 1 team Are Red Bull now the most successful F1 team ever – and how long can this dominance last? F1 chief hails ‘exciting’ development with Honda set for grid return ‘We must learn’: Neymar incident could see F1 clampdown on grid access Lewis Hamilton insists Mercedes must now switch focus to haul in Red Bull Are Red Bull the most successful F1 team ever – and how long can this dominance last?

First came the Big Red Boots, a cartoonish pair of shoes that invoked a lot